Core Insights - Upslope Capital Management reported a strong performance in Q3 2025, achieving a net return of +8.8%, outperforming the S&P Midcap 400 ETF and HFRX Equity Hedge Index [1] - The fund highlighted West Pharmaceutical Services, Inc. (NYSE:WST) as a key investment, noting its significant one-month return of 20.58% despite a 52-week decline of 7.20% [2][4] Company Overview - West Pharmaceutical Services, Inc. specializes in designing, manufacturing, and selling containment and delivery systems for injectable drugs and healthcare products [2] - As of October 22, 2025, West Pharmaceutical's stock closed at $277.00, with a market capitalization of $22.085 billion [2] Investment Thesis - The company is recognized as a leading producer of packaging and components for injectable drug delivery devices, benefiting from trends such as increased GLP-1 usage and advancements in drug development [3] - West Pharmaceutical has seen a de-rating in its valuation to approximately 23x 2026 EBITDA, which is considered reasonable given its consistent growth and competitive advantages [3] Market Position - West Pharmaceutical is not among the top 30 most popular stocks among hedge funds, with 46 hedge fund portfolios holding its shares at the end of Q2 2025, up from 40 in the previous quarter [4] - While the company shows potential, there are suggestions that certain AI stocks may offer greater upside potential with less downside risk [4]